For Inflammatory Diseases, Citryll and Lonza Partner to Develop Antibody - Pulmonary Fibrosis News

For Inflammatory Diseases, Citryll and Lonza Partner to Develop Antibody  Pulmonary Fibrosis News

Citryll and Lonza are teaming up to develop the antibody CIT-013 to treat inflammatory diseases, including idiopathic pulmonary fibrosis.



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases